Premium
Future of the drug label: Perspectives from a multistakeholder dialogue
Author(s) -
Gispende Wied Christine C.,
Weemers Just,
Boon Wouter,
Mol Peter G.M.,
Stolk Pieter
Publication year - 2019
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14070
Subject(s) - legislation , government (linguistics) , drug , pharmaceutical industry , state (computer science) , drug industry , business , medicine , public relations , pharmacology , political science , engineering ethics , engineering , computer science , law , philosophy , linguistics , algorithm
Regulating drugs does not end when market access has been granted. Monitoring drugs over the life cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing‐field and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry and patient/societal organizations was organized by the Regulatory Science Network Netherlands. This is their view.